The patent covers the core of the Oriel technology including design of Oriel’s dry powder inhalers containing multi-dose dry powder packages that can individually be activated to vibrate upon exposure to a customized electrical input. The design allows for potentially quicker and easier administration of inhaled therapies to treat respiratory and pulmonary diseases.
Oriel believes its dry powder inhalation technology will impact upon the way in which many respiratory illnesses will be treated. The technology allows for medications to be administered via inhalation which would traditionally only be administered via injection, for example insulin and some anti-infective agents.
The company currently has 11 US and associated international patent applications pending for a variety of aspects of the use of its fludization and aerosolization technology.